Ken Griffin Vaxcyte, Inc. Call Options Transaction History

Citadel Advisors LLC

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2024 Feb 14, 2025	BUY	$80.97 - $117.93 $412,947 - $601,443	5,100 Added 17.06%	35,000 $2.87 Million
Q3 2024 Nov 14, 2024	BUY	$70.52 - $117.12 $691,096 - $1.15 Million	9,800 Added 48.76%	29,900 $3.41 Million
Q2 2024 Aug 14, 2024	SELL	$60.06 - $78.77 $822,822 - $1.08 Million	-13,700 Reduced 40.53%	20,100 $1.52 Million
Q1 2024 May 15, 2024	BUY	$59.79 - $81.05 $1.61 Million - $2.19 Million	27,000 Added 397.06%	33,800 $2.31 Million
Q4 2023 Feb 14, 2024	BUY	$45.35 - $63.41 $36,280 - $50,728	800 Added 13.33%	6,800 $427,000
Q3 2023 Nov 14, 2023	SELL	$46.0 - $53.1 $50,600 - $58,410	-1,100 Reduced 15.49%	6,000 $305,000
Q2 2023 Aug 14, 2023	SELL	$34.66 - $54.07 $6,931 - $10,814	-200 Reduced 2.74%	7,100 $354,000
Q1 2023 May 15, 2023	SELL	$36.27 - $47.2 $5.73 Million - $7.46 Million	-158,100 Reduced 95.59%	7,300 $273,000
Q4 2022 Feb 14, 2023	SELL	$20.58 - $47.95 $372,497 - $867,895	-18,100 Reduced 9.86%	165,400 $7.93 Million
Q3 2022 Nov 14, 2022	SELL	$21.69 - $28.53 $10,845 - $14,265	-500 Reduced 0.27%	183,500 $4.4 Million

349

130M

539K

253K

Ticker PCVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,315,100
Market Cap $4.94B
Description
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.